Rohit Maidur

Employment

• SDM College of Medical Science and Hospital ASSOCIATE PROFESSOR
  2018 - 2024

Education

• NIMS DNB
  2014 - 2017

Projects & Funding

Projects & funding information is unavailable.

Publications (10)

• Durable complete response after discontinuation of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma with portal vein tumor thrombosis: the first report
  Journal of Liver Cancer 2025 DOI: 10.17998/jlc.2024.09.26
  +Save
• Lenvatinib Maintenance Therapy After Complete Response to Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma and Portal Vein Tumoral Thrombosis: Alternative Strategy in a Resource-limited Setting
  Journal of Clinical and Experimental Hepatology 2025 DOI: 10.1016/j.jceh.2024.102455
  +Save
• Portal Hypertension Due to TULP3-related Ciliopathy: First Report From the Asia–Pacific Region
  Journal of Clinical and Experimental Hepatology 2024 DOI: 10.1016/j.jceh.2024.101478
  +Save
• INCIDENCE OF INFLAMMATORY BOWEL DISEASE: A SINGLE CENTRE RETROSPECTIVE STUDY
  Arquivos de Gastroenterologia 2022 DOI: 10.1590/s0004-2803.202203000-63
  +Save
• Prospective Evaluation of Factors Affecting the Outcome in Cirrhotic Patients Requiring Intensive Care
  2021
  +Save
• Prospective evaluation of factors affecting the outcome in cirrhotic patients requiring intensive care
  2021
  +Save
• DAAs in Genotypes 2 and 3 of Chronic Hepatitis C—A Real World Experience
  Journal of Clinical and Experimental Hepatology 2016
  +Save
• Prospective Evaluation of Prognostic Factors in Cirrhotic Patients Requiring Intensive Care
  Journal of Clinical and Experimental Hepatology 2016
  +Save
• Serum Cholinesterase--An Old Wine in a New Bottle! A Marker to Differentiate Cirrhotic From Noncirrhotic Portal Hypertension
  Clinical Gastroenterology and Hepatology 2015
  +Save
• Serum Cholinesterase—An Old Wine in a New Bottle! A Marker to Differentiate Cirrhotic From Non-Cirrhotic Portal Hypertension
  Journal of Clinical and Experimental Hepatology 2015
  +Save